Study guide

2.2 Heart Failure Syndromes & Cardiogenic Shock

CAMC Regional Medical Registration Examination Part 1 MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Registration Framework & Test Strategy

1.1 Exam Format, Administration & Caribbean Medical Registration Pathways 1.2 Clinical Reasoning & Single-Best-Answer MCQ Test-Taking Strategy 1.3 Regional Epidemiology & Caribbean Healthcare Context

2 Chapter 2: Internal Medicine: Cardiovascular Disorders

2.1 Acute Coronary Syndromes & Myocardial Infarction Management 2.2 Heart Failure Syndromes & Cardiogenic Shock 2.3 Cardiac Arrhythmias, Conduction Blocks & BLS/ACLS Algorithms 2.4 Valvular Heart Disease, Infective Endocarditis & Hypertension

3 Chapter 3: Internal Medicine: Respiratory Medicine & Critical Care

3.1 Asthma & Chronic Obstructive Pulmonary Disease Exacerbations 3.2 Community-Acquired Pneumonia, Hospital-Acquired Pneumonia & Tuberculosis 3.3 Pulmonary Embolism, Pleural Effusion & Pneumothorax

4 Chapter 4: Internal Medicine: Endocrinology & Metabolic Disorders

4.1 Diabetes Mellitus, Diabetic Ketoacidosis & Hyperosmolar Hyperglycaemic State 4.2 Thyroid Disorders: Thyrotoxicosis, Hypothyroidism & Thyroid Storm 4.3 Adrenal Disorders, Pituitary Pathology & Calcium Homeostasis

5 Chapter 5: Internal Medicine: Gastroenterology, Hepatology & Nephrology

5.1 Upper & Lower Gastrointestinal Bleeding: Evaluation & Management 5.2 Cirrhosis, Portal Hypertension & Hepatic Encephalopathy 5.3 Acute Kidney Injury & Chronic Kidney Disease Staging 5.4 Fluid, Electrolyte & Acid-Base Emergencies

6 Chapter 6: Internal Medicine: Neurology, Haematology & Infectious Diseases

6.1 Stroke, Transient Ischaemic Attack & Acute Neurological Deficits 6.2 Sickle Cell Disease, Haemoglobinopathies & Transfusion Medicine 6.3 Dengue Fever, Arboviral Infections & Leptospirosis 6.4 HIV/AIDS, Opportunistic Infections & Antimicrobial Stewardship

7 Chapter 7: General Surgery: Acute Abdomen & Surgical Emergencies

7.1 Acute Abdomen: Peritonitis, Appendicitis & Acute Cholecystitis 7.2 Intestinal Obstruction, Bowel Ischaemia & Perforated Viscus 7.3 Abdominal Wall Hernias: Inguinal, Femoral, Umbilical & Strangulation 7.4 Upper & Lower GI Surgical Pathology & Postoperative Complications

8 Chapter 8: General Surgery: Trauma Resuscitation, Shock & Critical Care

8.1 ATLS Primary Survey & Hemorrhagic Shock Resuscitation 8.2 Thoracic Trauma: Tension Pneumothorax, Hemothorax & Flail Chest 8.3 Abdominal & Pelvic Trauma: FAST Examination & Damage Control Surgery 8.4 Traumatic Brain Injury, Burns & Wound Management

9 Chapter 9: General Surgery: Surgical Subspecialties & Perioperative Care

9.1 Urological Emergencies: Acute Retention, Renal Colic, Torsion & Hematuria 9.2 Musculoskeletal Trauma: Fractures, Dislocations & Compartment Syndrome 9.3 Preoperative Assessment, Surgical Site Infections & Fluid Management 9.4 Otolaryngology: Ear, Nose, Throat & Upper Airway Emergencies 9.5 Clinical Ophthalmology: Acute Red Eye, Glaucoma & Retinal Emergencies

10 Chapter 10: Obstetrics: Antenatal Care, Labor & Complications

10.1 Routine Antenatal Care, Screening & Fetal Assessment 10.2 Hypertensive Disorders of Pregnancy: Pre-eclampsia & Eclampsia 10.3 Antepartum Haemorrhage: Placenta Praevia & Placental Abruption 10.4 Normal Labor, Labor Dystocia & Obstetric Analgesia

11 Chapter 11: Obstetrics & Gynaecology: Postpartum & Pathology

11.1 Postpartum Haemorrhage, Normal Puerperium Physiology & Postpartum Care 11.2 Ectopic Pregnancy, Miscarriage & Gestational Trophoblastic Disease 11.3 Abnormal Uterine Bleeding & Pelvic Inflammatory Disease 11.4 Contraception, Cervical Cancer Screening & Gynaecological Malignancies 11.5 Obstetric & Gynaecological Instruments & Cervical Specimen Collection (PAP Smear Procedures)

12 Chapter 12: Paediatric Medicine: Neonatal Care, Growth & Nutrition

12.1 Neonatal Resuscitation, APGAR Scoring & Prematurity Complications 12.2 Neonatal Jaundice: Physiological, Pathological & Kernicterus 12.3 Growth Monitoring, Developmental Milestones & Failure to Thrive 12.4 Protein-Energy Malnutrition: Kwashiorkor, Marasmus & Nutritional Deficiencies

13 Chapter 13: Paediatric Medicine: Common Illnesses & Emergencies

13.1 Acute Gastroenteritis, Dehydration Assessment & WHO ORS Protocols 13.2 Paediatric Respiratory Illness: Croup, Bronchiolitis & Asthma 13.3 Childhood Infections, Exanthems & Caribbean Immunisation Schedules 13.4 Paediatric Surgical & Medical Emergencies: Intussusception & Febrile Seizures 13.5 Social Paediatrics, Child Protection & Vulnerable Child Health

14 Chapter 14: Psychiatry: Clinical Assessment & Psychopharmacology

14.1 Depressive Disorders, Bipolar Affective Disorder & Suicide Risk Assessment 14.2 Psychosis, Schizophrenia & Acute Delirium vs Dementia 14.3 Anxiety Disorders, Substance Misuse & Psychotropic Side Effects

15 Chapter 15: Community Health, Epidemiology & Preventive Medicine

15.1 Epidemiological Study Designs, Measures of Association & Bias 15.2 Screening Test Performance: Sensitivity, Specificity, PPV & NPV 15.3 Outbreak Investigation, Levels of Prevention & Caribbean NCD Control

16 Chapter 16: Internal Medicine: Rheumatology, Connective Tissue & Dermatology

16.1 Connective Tissue & Collagen Vascular Diseases 16.2 Bone & Joint Diseases: Non-Traumatic Arthropathies & Metabolic Bone Disorders 16.3 Clinical Dermatology: Common, Inflammatory, Bullous, Malignant & Drug-Induced Dermatoses

17 Chapter 17: Anaesthetics, Intensive Care & Clinical Measurements

17.1 Important Anaesthetic Techniques, Airway Management & Methods of Administration 17.2 Clinical Measurements & Intensive Care Monitoring: Cardiac Output, Arterial Blood Gases & Pulmonary Functions 17.3 Acute Pain Management, Multimodal Analgesia & Critical Care Sedation

2.2 Heart Failure Syndromes & Cardiogenic Shock

Key Takeaways Explain This Topic AI

AHA/ACC/HFSA 2022 uses HFrEF (LVEF <=40%), HFmrEF (41–49%) and HFpEF (>=50%). ESC 2026 instead uses HFrEF <50% and HFpEF >=50%, removing HFmrEF. Hypertension and ischaemic heart disease are important causes.

Clinical diagnosis relies on validated criteria such as the Framingham heart failure criteria and functional capacity grading using the New York Heart Association (NYHA) classification.

Treat acute congestion with IV loop diuretics and use vasodilators when blood pressure permits. Avoid starting or increasing beta-blockers during active decompensation; initiate or optimize them after clinical stabilization.

Guideline-directed medical therapy (GDMT) for HFrEF mandates the simultaneous or rapid sequential initiation of four foundational pillars: ARNI/ACEi, evidence-based beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors.

Cardiogenic shock is cardiac pump failure with tissue hypoperfusion. Assess perfusion and congestion separately; a cold/dry profile can represent euvolemic pump failure or RV dysfunction, rather than hypovolemia.

Last updated: November 2026

Pathophysiology & Classification: HFrEF vs. HFpEF

Heart failure is a complex clinical syndrome characterized by cardinal symptoms (dyspnea, fatigue, ankle swelling) and clinical signs (elevated jugular venous pressure, pulmonary crackles, peripheral edema) resulting from structural or functional abnormalities of the heart. These abnormalities lead to elevated intracardiac pressures and inadequate cardiac output at rest or during physiological exertion.

The following 2022 AHA/ACC/HFSA categories use echocardiographic left ventricular ejection fraction (LVEF). ESC 2026 instead defines HFrEF as LVEF <50% and HFpEF as >=50%, removing HFmrEF; use the framework named in the question:

Heart Failure with Reduced Ejection Fraction (HFrEF) : Defined as LVEF <= 40%. Characterized primarily by systolic dysfunction—inadequate myocardial contractility and left ventricular dilatation (eccentric hypertrophy). Ischemic heart disease, dilated cardiomyopathy, and advanced hypertensive remodeling are predominant etiologies.

Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF) : Defined as LVEF 41% to 49%. Shares overlapping pathophysiological characteristics with HFrEF and demonstrates similar benefit from neurohormonal therapies.

Heart Failure with Preserved Ejection Fraction (HFpEF) : Defined as LVEF >= 50% accompanied by objective evidence of cardiac structural changes (left atrial enlargement, left ventricular concentric hypertrophy) and diastolic dysfunction (elevated filling pressures, abnormal E/e' ratio on Doppler echocardiography). In Caribbean regional practice, chronic uncontrolled hypertension, metabolic syndrome, obesity, and diabetes mellitus are principal drivers of HFpEF.

Neurohormonal Activation

Following myocardial injury, a sustained decline in stroke volume unloads arterial baroreceptors, triggering compensatory neurohormonal pathways:

Renin-Angiotensin-Aldosterone System (RAAS) : Enhanced renin release increases circulating angiotensin II (provoking arteriolar vasoconstriction, afterload elevation, and cellular hypertrophy) and aldosterone (promoting renal tubular sodium-water retention and progressive myocardial fibrosis).

Sympathetic Nervous System (SNS) : Chronic adrenergic overdrive drives tachycardia, increases myocardial oxygen consumption, induces beta-1 receptor downregulation, and promotes fatal ventricular arrhythmias.

Natriuretic Peptide System : Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are released from stretched atria and ventricles to facilitate natriuresis, vasodilation, and RAAS suppression. Endogenous neutral endopeptidase ( neprilysin ) rapidly degrades these beneficial peptides, forming the rationale for therapeutic neprilysin inhibition.

Clinical Evaluation & Staging

Diagnosis requires a synthesized evaluation of clinical signs, symptoms, electrocardiography, chest radiography, biomarkers, and transthoracic echocardiography.

Framingham Heart Failure Diagnostic Criteria

For the Framingham definition, use two major criteria or one major plus two minor criteria present concurrently, considering whether other conditions explain the findings.

Major Criteria : Paroxysmal nocturnal dyspnea (PND) or orthopnea (one major criterion); elevated jugular venous pressure (> 4 cm above sternal angle); pulmonary rales; cardiomegaly on chest radiograph; acute pulmonary edema; S3 gallop; hepatojugular reflux; weight loss >= 4.5 kg in 5 days in response to treatment.

Minor Criteria : Bilateral ankle edema; nocturnal cough; dyspnea on ordinary exertion; hepatomegaly; pleural effusion; tachycardia (heart rate >= 120 bpm); decrease in vital capacity by one-third from maximum.

Functional & Staging Classifications

NYHA Functional Classification : Grades symptom severity relative to physical activity:

Class I : No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea.

Class II : Slight limitation of physical activity. Comfortable at rest, but ordinary activity results in fatigue, palpitation, or dyspnea.

Class III : Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes symptoms.

Class IV : Unable to carry on any physical activity without discomfort. Symptoms of heart failure present even at rest.

ACC/AHA Staging System : Highlights progressive structural trajectory:

Stage A : At risk for heart failure without structural disease or symptoms (e.g., hypertension, diabetes).

Stage B : Pre-heart failure: structural heart disease (e.g., prior MI, LVH) without symptoms.

Stage C : Structural heart disease with prior or current clinical symptoms.

Stage D : Advanced, refractory heart failure requiring specialized interventions (inotropes, mechanical assist devices, palliative care).

Biomarkers in Heart Failure

Circulating B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) serve as sensitive biochemical markers of myocardial wall stress. In acute presentation, thresholds of BNP < 100 pg/mL or NT-proBNP < 300 pg/mL exhibit high negative predictive value (> 95%) to rule out acute heart failure. Notably, patients receiving sacubitril/valsartan demonstrate elevated BNP (as sacubitril inhibits its degradation), while NT-proBNP is not a neprilysin substrate and remains an accurate monitoring marker.

Acute Decompensated Heart Failure (ADHF) Management

Acute decompensated heart failure presents as acute pulmonary edema, worsening congestion, or low cardiac output. Patients must be rapidly evaluated for precipitating causes using the CHAMPIT mnemonic (Coronary syndrome, Hypertensive crisis, Arrhythmia, Mechanical cause, Pulmonary embolism, Infection, Tamponade).

Immediate Resuscitation Sequence

Patient Positioning : Place the patient in a high Fowler's (sitting upright) position with legs dangling over the edge of the bed to promote peripheral venous pooling and reduce right and left ventricular preload.

Non-Invasive Positive Pressure Ventilation (NIPPV) : Continuous Positive Airway Pressure (CPAP 5-10 cmH2O) or Bilevel Positive Airway Pressure (BiPAP) should be initiated early in patients with respiratory distress (tachypnea > 25 breaths/min, SpO2 < 90%). NIPPV improves functional residual capacity, drives fluid back from alveoli into interstitial capillaries, decreases work of breathing, and reduces left ventricular afterload by lowering transmural wall tension, substantially reducing the need for invasive endotracheal intubation.

Intravenous Loop Diuretics : The cornerstone of acute decongestion. Administer IV furosemide immediately. For diuretic-naive patients, an initial dose of 20 to 40 mg IV is given. For patients on chronic oral therapy, the initial IV bolus should equal 1.0 to 2.5 times their total daily oral dose given as an intravenous bolus (e.g., if taking 40 mg PO daily, administer 40 to 100 mg IV). Furosemide induces rapid venodilation within 5 to 15 minutes before its natriuretic peak occurs at 30 to 60 minutes. Adequacy of diuresis is evaluated by spot urine sodium (> 50-70 mEq/L at 2 hours) and hourly urine output (> 100-150 mL/h).

Intravenous Vasodilators : In patients with acute hypertensive pulmonary edema (systolic blood pressure > 110 mmHg), intravenous nitroglycerin (starting at 10-20 mcg/min and uptitrated rapidly by 10-20 mcg/min every 3-5 minutes) provides potent venodilation and arteriolar dilation, reducing intracardiac filling pressures rapidly.

Critical Beta-Blocker Rule : Do not initiate or increase beta-blockers during ongoing acute congestion, hypoperfusion or shock. Continue established treatment when clinically stable, but reassess or withhold it for shock, marked bradycardia, second- or third-degree AV block, or significant intolerance. Initiate or optimize an evidence-based beta-blocker after stabilization, often before hospital discharge.

Guideline-Directed Medical Therapy (GDMT): The Four Pillars

For chronic HFrEF (LVEF <= 40%), contemporary international guidelines mandate the rapid initiation and titration of four foundational pharmacotherapeutic classes proven to reduce all-cause mortality, cardiovascular death, and heart failure hospitalization:

GDMT Pillar Representative Agents & Doses Mechanism of Benefit Crucial Clinical Pearls & Contraindications

1. ARNI / ACEi / ARB Sacubitril/Valsartan (initial 24/26 mg or 49/51 mg BID; target 97/103 mg BID); or Ramipril (target 10 mg daily); or Enalapril (target 10 mg BID) ARNI simultaneously inhibits neprilysin (increasing natriuretic peptides, bradykinin, and adrenomedullin) and blocks the AT1 receptor. Sacubitril/Valsartan is superior to ACEi monotherapy (PARADIGM-HF trial). When switching from an ACE inhibitor to an ARNI, a strict 36-hour washout period is mandatory to prevent life-threatening angioedema. Contraindicated in pregnancy and bilateral renal artery stenosis.

2. Evidence-Based Beta-Blockers Bisoprolol (target 10 mg daily); Carvedilol (target 25-50 mg BID); Metoprolol Succinate (target 200 mg daily) Inhibits chronic sympathetic hyperactivation, reverses adverse remodeling, improves LVEF, and prevents ventricular tachyarrhythmias. Only these three specific beta-blockers demonstrate mortality reduction in HFrEF (atenolol and short-acting metoprolol tartrate do not). Initiate only in clinically euvolemic, stable patients at low starting doses and double every 2 weeks.

3. Mineralocorticoid Receptor Antagonists (MRA) Spironolactone (initial 12.5-25 mg daily; target 25-50 mg daily); Eplerenone (target 50 mg daily) Blocks aldosterone-mediated sodium retention, potassium wasting, and myocardial and vascular endothelial fibrosis. Reduces mortality in NYHA II-IV HFrEF. Check serum potassium and renal function at baseline, 1 week, 4 weeks, and periodically. Initiate only if potassium <5.0 mEq/L and eGFR >30 mL/min/1.73m2 ; discontinue if potassium cannot be maintained <5.5 mEq/L . Eplerenone avoids anti-androgenic gynecomastia.

4. SGLT2 Inhibitors Dapagliflozin (10 mg once daily); Empagliflozin (10 mg once daily) Promotes osmotic diuresis, alters myocardial energetics toward ketone bodies, reduces afterload, and decreases intrarenal glomerular pressure. Demonstrates striking mortality and hospitalization reductions regardless of diabetes status (DAPA-HF, EMPEROR-Reduced trials). Minimal effect on blood pressure; does not cause hypoglycemia in non-diabetics. Check for euglycemic DKA risk in insulin-deficient patients.

Cardiogenic Shock & Forrester Hemodynamic Profiling

Cardiogenic shock is a state of critical end-organ tissue hypoperfusion caused by primary cardiac pump failure. Typical findings considered alongside the clinical assessment include:

Sustained systolic blood pressure < 90 mmHg (or mean arterial pressure < 65 mmHg) for > 30 minutes, or requirement of inotropes/vasopressors to maintain blood pressure.

Reduced Cardiac Index (typically CI <2.2 L/min/m2 ), interpreted with the clinical state and any hemodynamic support.

Elevated Pulmonary Capillary Wedge Pressure ( PCWP >15 mmHg ) is common in LV failure; PCWP may be normal with euvolemic or predominantly RV cardiogenic shock.

Clinical signs of hypoperfusion: Cool extremities, mottled skin, oliguria (< 0.5 mL/kg/h), altered mental status, and elevated serum lactate (> 2.0 mmol/L).

The Forrester Hemodynamic Classification

The Forrester classification stratifies heart failure and shock patients into four quadrants based on physical examination and invasive hemodynamics (perfusion [warm vs cold] and congestion [dry vs wet]):

Subset I: Warm & Dry (Cardiac Index > 2.2 L/min/m2, PCWP <= 18 mmHg). Normal hemodynamics or compensated heart failure. Maintain GDMT.

Subset II: Warm & Wet (Cardiac Index > 2.2, PCWP > 18 mmHg). Congested with preserved perfusion. Treated with intravenous loop diuretics and vasodilators (nitroglycerin).

Subset III: Cold & Dry (Cardiac Index <= 2.2, PCWP <= 18 mmHg). Hypoperfused without elevated pulmonary filling pressure. Assess preload and RV function; give a cautious fluid challenge (for example, 250 mL) only if underfilling is likely, and consider inotropic support for persistent pump failure.

Subset IV: Cold & Wet (Cardiac Index <= 2.2, PCWP > 18 mmHg). Classic congested low-output profile. Use vasopressor support for hypotension and an inotrope when needed, reassessing perfusion and considering mechanical support; address congestion as circulation stabilizes.

Inotropes and Vasopressors in Cardiogenic Shock

First-Line Vasopressor: Noradrenaline (Norepinephrine) . Potent alpha-1 agonist with modest beta-1 activity. Increases MAP and coronary perfusion pressure without excessive tachycardia, demonstrating lower arrhythmic risk and lower mortality compared to dopamine.

First-Line Inotrope: Dobutamine . Beta-1 and beta-2 adrenergic agonist. Increases myocardial contractility and stroke volume while producing mild peripheral vasodilation (afterload reduction). In patients with severe hypotension (MAP < 65 mmHg), dobutamine must be paired with noradrenaline to avoid worsening vasodilatory hypotension.

Alternative Inotrope: Milrinone . Phosphodiesterase-3 (PDE-3) inhibitor. Enhances cyclic AMP, increasing inotropy and lusitropy (diastolic relaxation) while reducing systemic and pulmonary vascular resistance. Ideal in pulmonary hypertension or chronic beta-blocker therapy, but renally cleared and can cause prolonged hypotension; vasopressor support depends on blood pressure and perfusion.

Loading diagram... Forrester Hemodynamic Subsets & Therapeutic Strategy